Accessibility Menu
Proteome Sciences Plc logo

Proteome Sciences Plc(LSE) PRM

Market Cap£6.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1995)-99%
5 Year-68%
1 Year-41%
1 Month+9%
£0.02
+2.6%
+0.00Today
Proteome Sciences Plc last closing stock price
MetricPriceDate
Last closeGBX 1.802026-07-30
Proteome Sciences Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.26%GBX 1.902026-07-23
1 month+9.09%GBX 1.652026-06-30
3 month+7.14%GBX 1.682026-05-01
Year to date-28%GBX 2.502025-12-31
1 year-40.79%GBX 3.042025-07-30
3 year-75.94%GBX 7.482023-07-31
5 year-67.86%GBX 5.602021-07-30
Since inception-98.79%GBX 1.481995-10-03

Proteome Sciences Plc Financials at a Glance

Market Cap

£6.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£8.64M

Net Income (TTM)

-£6.47M

EPS (TTM)

-£0.01

P/E Ratio

-1.73

Dividend

£0.00

Beta (Volatility)

0.01 (Low)

Price

£0.02

Volume

1,000

Open

£0.02

Previous Close

£0.02

Daily Range

£0.02 - £0.02

52-Week Range

£0.01 - £0.04

Estimated Earnings Date

Aug 28, 2024

PRM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Proteome Sciences Plc

Proteome Sciences Plc engages in the applied proteomics and peptidomics services and applications. It offers proprietary technologies for protein and peptide biomarker discovery, validation, and assay development. The company focuses on developing proprietary protein biomarkers for neurological diseases, oncology, and organ transplant rejection. Proteome Sciences was founded on December 10, 1993 and is headquartered in Addlestone, the United Kingdom.

Industry

Life Sciences Tools and Services

CEO

Mariola Söhngen, MD

Headquarters

Cobham, SU KT11 3EP, GB

PRM Financials

Key Financial Metrics (TTM)

Gross Margin

-26.81%

Operating Margin

-70.98%

Net Income Margin

-81.50%

Return on Equity

33.80%

Return on Capital

-42.73%

Return on Assets

-37.08%

Earnings Yield

-57.80%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£6.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

350.73M

Volume

1.00K

Avg. Volume

386.58K

Financials (TTM)

Gross Profit

-£1.17M

Operating Income

-£5.02M

EBITDA

-£3.26M

Operating Cash Flow

-£872.00K

Capital Expenditure

-£321.00K

Free Cash Flow

-£1.19M

Cash & ST Invst.

£781.00K

Total Debt

£15.77M

Proteome Sciences Plc Performance Analysis

Proteome Sciences Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 7,780,00051.8%
20232023-12-31GBP 5,028,000-35.4%
20242024-12-31GBP 4,887,000-2.8%
20252025-12-31GBP 3,756,000-23.1%
Proteome Sciences Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3021.9%
Q42024-12-3120.4%
Q22025-06-30-30.4%
Q42025-12-312.3%
Proteome Sciences Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 0.002050.0%
20232023-12-31GBP -0.01N/A
20242024-12-31GBP -0.0138.6%
20252025-12-31GBP -0.01-9.6%
Proteome Sciences Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-19.0%
Q42024-12-3146.7%
Q22025-06-30-80.0%
Q42025-12-3155.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£1.90M

+4.5%

Gross Profit

-£917.00K

-664.2%

Gross Margin

-48.29%

N/A

Market Cap

£6.31MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£197.28K

N/A

Employees

32

N/A

Net Income

-£921.00K

+50.6%

EBITDA

-£532.00K

+57.8%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£781.00K

-61.5%

Total Debt

£15.77M

+17.0%

Accounts Receivable

£754.00K

-28.2%

Inventory

£537.00K

-35.8%

Long Term Debt

£824.00K

-49.5%

Short Term Debt

£14.95M

+26.2%

Return on Assets

-37.08%

N/A

Return on Invested Capital

32.06%

N/A

Free Cash Flow

£812.00K

+100.0%

Operating Cash Flow

£851.00K

+100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
GDR.LGenedrive Plc
£0.01+7.69%
TRX.LTissue Regenix Group plc
£0.07+0.00%
SUN.LSurgical Innovations Group plc
£0.01+0.00%
TCF.LTheracryf Plc
£0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.13+0.11%
NVDANvidia
$195.04+0.03%
MSFTMicrosoft
$451.10+0.16%
NOKNokia
$9.09+0.08%

Questions About PRM

What is the current price of Proteome Sciences Plc?

Proteome Sciences Plc is trading at £0.02 per share.

What is the 52-week range for Proteome Sciences Plc?

Over the past 52 weeks, Proteome Sciences Plc has traded between £0.01 and £0.04.

How much debt does Proteome Sciences Plc have?

As of the most recent reporting period, Proteome Sciences Plc reported total debt of £15.77M.

How much cash does Proteome Sciences Plc have on hand?

Proteome Sciences Plc reported £781.00K in cash and cash equivalents in its most recent financial results.

What is Proteome Sciences Plc’s dividend yield?

Proteome Sciences Plc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.